Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04940611
Other study ID # Alofisel-5007
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date August 5, 2021
Est. completion date May 2, 2026

Study information

Verified date April 2024
Source Takeda
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

In this study, participants with complex fistulizing conditions will be treated with surgical interventions according to their clinic's standard practice. The aim of the study is to generate real-world evidence on standard of care for surgical interventions and related outcomes when treating complex fistulizing conditions. The study sponsor will not be involved in how participants are treated but will provide instructions on how the clinics will record what happens during the study.


Description:

This is a non-interventional, prospective study of participants with complex fistulizing conditions (CPF-CD, CD develops CD-RVF and CCF) who are currently undergoing surgical intervention in the real world clinical setting. The study will enroll approximately 750 participants. The data will be collected prospectively at the study sites and will be recorded into electronic data capture forms (EDCs). Participants will be enrolled to the following observational cohorts: - Participants With CPF-CD - Participants With CD-RVF - Participants With CCF This multi-center study will be conducted in the United States, Canada, Europe, and Israel. Participants undergoing surgical interventions to treat fistulas will be enrolled from surgical and gastrointestinal (GI) specialty sites. The overall duration of the study will be 24 months. Data will be collected at baseline with follow-up information collected approximately every 3 to 6 months.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 750
Est. completion date May 2, 2026
Est. primary completion date May 2, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Participants with CPF-CD 1. CPF-CD that meets one or more of the following criteria: - High inter-sphincteric, high trans-sphincteric, extra-sphincteric or supra-sphincteric fistula, or - Presence of greater than or equal to (>=) 2 external openings, or - Associated perianal abscess(es) 2. Physician has made the decision to treat with a specific surgical intervention. Procedures may include: - Fistulotomy, fistula plug, fibrin glue, advancement flap (AF), ligation of inter-sphincteric fistula tract (LIFT), flap repair, fistulectomy, proctectomy, stem cell therapy, other; and seton for palliative purposes. Participants with CD-RVF: Rectovaginal fistula per physician diagnosis 1. Physician has made the decision to treat with a specific surgical intervention. Procedures may include: - Fistulotomy, fistula plug, fibrin glue, AF, LIFT, flap repair, fistulectomy, proctectomy, stem cell therapy, gracilis muscle interposition/tissue grafts, martius procedure, abdominal procedures, other; and seton use for palliative purposes. Participants with CCF: 1. Complex cryptoglandular fistula that meets one or more of the following criteria: - Mid or high trans-sphincteric, or - Anterior in women, or - Horseshoe fistula 2. Physician has made the decision to treat with a specific surgical intervention. Procedures may include: - Fistulotomy, fistula plug, fibrin glue, AF, LIFT, flap repair, fistulectomy, proctectomy, stem cell therapy, other; and seton use for palliative purposes Exclusion Criteria: Participants who meet any below mentioned criterion among CPF-CD, CD-RVF, and CCF diagnosis will be excluded from the study. 1. Current participation in interventional clinical trials. 2. Has CPF-CD: fistula connection to bladder or another organ 3. Has CCF: diagnosis of Inflammatory Bowel Disease (IBD), including Ulcerative Colitis, and Crohn's Disease (CD).

Study Design


Locations

Country Name City State
Austria AKH - Medizinische Universitat Wien Vienna
Belgium UZ Antwerpen Antwerp
Belgium Cliniques Universitaires Saint-Luc Brussels
Belgium Jessa Ziekenhuis Hospital Hasselt
Belgium Clinique CHC MontLegia Liege
Belgium AZ Delta Roeselare
Canada St. Pauls Hospital Vancouver British Columbia
Czechia Fakultni nemocnice Brno Brno
Czechia Fakultni nemocnice u sv. Anny v Brne Brno
Czechia NH Hospital a.s.Nemocnice Horovice Horovice
Czechia Fakultni nemocnice Olomouc Olomouc
France CHRU Hopital Claude Huriez Lille Nord
France Groupe Hospitalier Diaconesses - Hopital De La Croix Saint Simon Paris
France Hopital Saint Joseph - Paris Paris
France Hospices Civils de Lyon (HCL) - Centre Hospitalier Lyon-Sud Pierre-Benite Bouches-du-Rhone
France CHU de Rennes - Hopital Pontchaillou Rennes cedex 09 Ille Et Vilaine
France CHU de Rouen - Hopital Charles Nicolle Rouen Cedex Seine Maritime
France Fondation Maison Sante Bagatelle Talence Gironde
Israel Shamir Medical Center (Assaf Harofeh) Be'er Ya'aqov
Israel Rambam Health Care Center Haifa
Israel Wolfson Medical Center Holon
Israel Tel Aviv Sourasky Medical Center Tel Aviv
Italy Istituto Clinico Humanitas Rozzano Milano
Netherlands Amsterdam UMC, Locatie AMC Amsterdam
Netherlands UMC Utrecht Utrecht
United Kingdom Broomfield Hospital Chelmsford Essex
United Kingdom Royal Victoria Infirmary. Newcastle upon Tyne Tyne & Wear
United Kingdom Nottingham University Hospital Nottingham Nottinghamshire
United States GI Alliance - Baton Rouge Baton Rouge Louisiana
United States UNC Hospitals Chapel Hill North Carolina
United States Baylor Research Institute Dallas Texas
United States Premier Health Dayton Ohio
United States Colon & Rectal Clinic Houston Texas
United States Baptist MD Anderson Cancer Center Jacksonville Florida
United States University of Kansas Medical Center Research Institute, Inc. Kansas City Kansas
United States Cedars-Sinai Medical Center Los Angeles California
United States Vanderbilt University Medical Center- GI Endoscopy Lab Nashville Tennessee
United States Lenox Hill Hospital PRIME New York New York
United States Penn Medicine PA Philadelphia Pennsylvania
United States Temple University Hospital Philadelphia Pennsylvania
United States University of South Florida - PARENT Tampa Florida

Sponsors (1)

Lead Sponsor Collaborator
Takeda

Countries where clinical trial is conducted

United States,  Austria,  Belgium,  Canada,  Czechia,  France,  Israel,  Italy,  Netherlands,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants who Achieve Clinical Remission of Fistula Clinical remission for Complex perianal fistula in Crohn's Disease (CPF-CD) and Complex Cryptoglandular Fistula (CCF) is defined as closure of all index treated external fistula openings that were draining at baseline as assessed clinically despite gentle finger compression. Clinical remission for Rectovaginal fistula with Crohn's Disease (CD-RVF) is defined as epithelization of the index external fistula opening (vaginal opening) compared to baseline. Baseline up to 24 months
Secondary Percentage of Participants With Post-surgical Complications Post-surgical complications for CPF-CD and CCF is defined as post-index surgery perianal pain, bleeding, infection, urinary retention, delayed or poor wound healing, anal stenosis, and fecal incontinence related to index surgery. Post-surgical complications for CD-RVF is defined as post-index surgery vaginal bleeding, infection, urinary retention, urinary tract infections (UTIs), discharge, delayed or poor wound healing, anal stenosis, fecal incontinence, and pain with intercourse or others related to index surgery. Baseline, 3, 6, 12 and 24 months post-index surgery
Secondary Percentage of Participants who Achieve Combined Remission Combined remission for CPF-CD and CCF is defined as closure of all index external fistula openings treated with surgery that were draining at baseline as assessed clinically despite gentle finger compression, and absence of fluid collections greater than (>) 2 centimeter (cm) in at least 2 dimensions, as confirmed by pelvic magnetic resonance imaging (MRI) or other imaging procedure. Combined remission for CD-RVF is defined as 100 percent (%) cessation of drainage on both clinical exam with deep palpation (deeper bimanual exam/palpation with speculum and/or anoscope) and epithelization of the index external fistula opening (vaginal opening) compared to baseline; and absence of fluid collection as assessed by MRI or other imaging procedure. Baseline, 3, 6, 12 and 24 months post-index surgery
Secondary Percentage of Participants who Achieve Cessation of Drainage in Treated Fistula Cessation of drainage for CPF-CD and CCF is defined as 100% cessation of drainage from index treated fistula, as assessed clinically. Cessation of drainage for CD-RVF is defined as 100% cessation of drainage on clinical exam with deep palpation (deeper bimanual exam/palpation with speculum and/or anoscope) from the index treated fistula. Baseline, 3, 6, 12 and 24 months post-index surgery
Secondary Percentage of Participants With Relapse of Fistula in Clinical Remission Relapse for CPF-CD and CCF is defined as reopening of any surgically treated index fistulae as clinically assessed; or the development of a perianal fluid collection >2 cm in at least 2 dimensions of the perianal fistula(s) treated, confirmed by MRI assessment or other imaging procedure; or drainage. Relapse for CD-RVF is defined as reopening of any surgically treated index fistulae as clinically assessed; or appearance of fluid collection as assessed by MRI or other imaging procedure; or drainage. Baseline, 3, 6, 12 and 24 months post-index surgery
Secondary Percentage of Participants With New Perianal Abscess Baseline, 3, 6, 12 and 24 months post-index surgery
See also
  Status Clinical Trial Phase
Completed NCT02685878 - Outcomes of Women After Obstetric Fistula Repair
Completed NCT02962141 - A Study of Hemodialysis Arteriovenous Fistulae Stenosis Treated With APERTO N/A
Completed NCT02770352 - Fistula Formation and Successful Repair
Recruiting NCT01388257 - Anal Crohn Fistula Surgery N/A
Completed NCT00544492 - Study of Pain, Anxiety and Complications Related to Cannulation of Arteriovenous (AV) Fistula in Chronic Hemodialysis Patients Phase 4
Recruiting NCT05616104 - FLEX FIRST Registry Research Protocol
Completed NCT00500968 - Study Assessing the Effect of Transpapillary Pancreas Duct Stent in Resection of the Pancreatic Tail N/A
Completed NCT05602987 - Comparison Study of the Effect of Enema in Anal Surgery N/A
Recruiting NCT04543539 - IN.PACTâ„¢ AV Access Post-Approval Study (PAS002)
Terminated NCT01321866 - Cutting Balloon Versus Non-cutting Balloon for the Treatment of Venous Stenosis in the Fistulas of Hemodialyzed Patients N/A
Recruiting NCT06413836 - Evaluation of Photodynamic Therapy in Pieces With Presence of Fistula. N/A
Recruiting NCT05766566 - Treatment of Perianal Fistulas in Crohn's Disease With Autologous Microfragmented Adipose Tissue With the Lipogems System
Withdrawn NCT03685955 - Efficacy of Amniotic Membranes in Complex Genitourinary Reconstruction
Completed NCT02374762 - Hemodialysis Vascular Access Imaging Study N/A
Not yet recruiting NCT04774588 - HoloStream Study - Video Capture Device Usage N/A
Completed NCT03120689 - VITOM Study: A Randomized, Controlled Trial. N/A
Completed NCT01144962 - Dose-escalating Therapeutic Study of Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Fistulas in Patients With Refractory Perianal Crohn's Disease Phase 1/Phase 2
Not yet recruiting NCT00653094 - An Open Label, Prospective, One Arm, Feasibility, Study for The Use of Halevy Kit for the Treatment of Perianal Fistulas in Patients With Crohn's Disease N/A
Active, not recruiting NCT05418816 - SelfWrap-Assisted Arteriovenous Fistulas N/A
Withdrawn NCT04073472 - Mesenchymal Stem Cells for the Treatment of Pouch Fistulas in Crohn's Phase 1